References
- Wilson JS, Gains JE, Moroz V, et al. A systematic review of 131I-metaiodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer. 2014;50(4):801–815.
- Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322(8):746–755.
- Mastrangelo R, Tornesello A, Mastrangelo S. Role of 131I-metaiodobenzylguanidine in the treatment of neuroblastoma. Med Pediatr Oncol. 1998;31(1):22–26.
- Goldie JH, Coldman AJ. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep. 1983;67:923–931.
- Mastrangelo S, Tornesello A, Diociaiuti L. et al. Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma. Q J Nucl Med. 1995;39(4 Suppl 1):69–71.
- Mastrangelo R, Tornesello A, Riccardi R, et al. A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer. 1995;31A(4):606–611.
- Mastrangelo R, Tornesello A, Lasorella A, et al. Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neurooncol. 1997;31:153–158.
- Mastrangelo S, Tornesello A, Bembo V, et al. Radioresistant sensitization of neuroblastoma by cisplatin? Med Pediatr Oncol. 2000;35(1):77–79.
- Mastrangelo S, Servidei T, Iavarone A, et al. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: a review. Inter J Pediatr Hematol Oncol. 1996;3:287–296.
- Mastrangelo S, Tornesello A, Diociaiuti L, et al., Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer. 2001;84(4):460–464.
- Millar JL, Hudspith BN. Sparing effect of cyclophosphamide (NSC-26271) pretreatment on animals lethally treated with gamma-irradiation. Cancer Treat Rep. 1976;60:409–414.
- Mastrangelo S, Rufini V, Ruggiero A, et al., Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen. Pediatr Blood Cancer. 2011;56(7):1032–1040.
- Ladenstein R, Pötschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1617–1629.
- De Kraker J, Hoefnagel KA, Verschuur AC, et al. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer. 2008;44:551–556.
- Lee JW, Lee S, Cho HW, et al. Incorporation of high-dose 131 I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol. 2017;10(1):108.
- Kraal KC, Tytgat GA, van Eck-Smit BL, et al. Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan. Pediatr Blood Cancer. 2015;62(11):1886–1891.
- Schmidt M, Simon T, Hero B, et al. The prognostic impact of functional imaging with (123) I-mIBGin patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German neuroblastoma trial NB97. Eur J Cancer. 2008;44(11):1552–1558.
- Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9(3):247–256.